Life expectancy of HIV-positive Canadians rises to 65 years: study

A new study provides more evidence that an HIV diagnosis is no longer the all-but-certain death sentence of years past.

Researchers say the overall life expectancy of Canadians undergoing antiretroviral treatment for HIV, the virus that causes AIDS, has climbed to 65 years.

The study also reinforces the effectiveness of starting antiretroviral treatment early.

Dr. Julio Montaner, director of the BC Centre for Excellence in HIV/AIDS, says treatment not only improves the health of people living with HIV, but also reduces its transmission.

The study’s principal investigator, Dr. Robert Hogg, adds that treatment providers must nonetheless remain vigilant in ensuring therapy reaches everyone, particularly vulnerable groups such as injection drug users.

The study shows that life expectancy increased less for women, injection drug users and people with First Nations ancestry.

Scroll to Top

During the Canada Post strike announced September 25, 2025, the following measures will be undertaken to minimize service disruption to BC-CfE clients and providers.

  • The BC-CfE Laboratory has transitioned to private courier for delivery of outgoing reports and documents. Results required urgently can be faxed upon request. (Lab Contact Information: Phone 604-806-8775; FAX 604-806-9463)
  • The BC-CfE Drug Treatment Program (DTP) will fax outgoing forms and documents to the provider’s office. (DTP Contact Information: Phone 604-806-8515; FAX 604-806-9044)
  • St. Paul’s Hospital Ambulatory Pharmacy has transitioned to private courier for delivery of medications. We recommend requesting medication at least 2 weeks in advance in case of delivery delays, particularly to rural/remote parts of BC. (Contact Information: Phone 1-800-547-3622; FAX 604-806-8675)

During the Canada Post strike, we recommend that documents be faxed or couriered to our sites, versus utilization of regular mail service

The BC-CfE Laboratory is streamlining reporting processes for certain tests in order to simplify distribution and record-keeping, and to ensure completeness of results. Beginning September 2, 2025, results for the ‘Resistance Analysis of HIV-1 Protease and Reverse Transcriptase’ (Protease-RT) and ‘HIV-1 Integrase Resistance Genotype’ tests will be combined into a single ‘HIV-1 Resistance Genotype Report’.
For more details and example reports, please click on the button below